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Abstract
Background: Cognitive decline is among the most feared treatment-related outcomes of older adults with cancer.
The majority of older patients with breast cancer self-report cognitive problems during and after chemotherapy.
Prior neuroimaging research has been performed mostly in younger patients with cancer. The purpose of this study
was to evaluate longitudinal changes in brain volumes and cognition in older women with breast cancer receiving
adjuvant chemotherapy.
Methods: Women aged ≥ 60 years with stage I–III breast cancer receiving adjuvant chemotherapy and age-
matched and sex-matched healthy controls were enrolled. All participants underwent neuropsychological testing
with the US National Institutes of Health (NIH) Toolbox for Cognition and brain magnetic resonance imaging (MRI)
prior to chemotherapy, and again around one month after the last infusion of chemotherapy. Brain volumes were
measured using Neuroreader™ software. Longitudinal changes in brain volumes and neuropsychological scores
were analyzed utilizing linear mixed models.
Results: A total of 16 patients with breast cancer (mean age 67.0, SD 5.39 years) and 14 age-matched and
sex-matched healthy controls (mean age 67.8, SD 5.24 years) were included: 7 patients received docetaxel and
cyclophosphamide (TC) and 9 received chemotherapy regimens other than TC (non-TC). There were no
significant differences in segmented brain volumes between the healthy control group and the chemotherapy
group pre-chemotherapy (p > 0.05). Exploratory hypothesis generating analyses focusing on the effect of the
chemotherapy regimen demonstrated that the TC group had greater volume reduction in the temporal lobe
(change = − 0.26) compared to the non-TC group (change = 0.04, p for interaction = 0.02) and healthy controls
(change = 0.08, p for interaction = 0.004). Similarly, the TC group had a decrease in oral reading recognition
scores (change = − 6.94) compared to the non-TC group (change = − 1.21, p for interaction = 0.07) and healthy
controls (change = 0.09, p for interaction = 0.02).
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Conclusions: There were no significant differences in segmented brain volumes between the healthy control
group and the chemotherapy group; however, exploratory analyses demonstrated a reduction in both
temporal lobe volume and oral reading recognition scores among patients on the TC regimen. These results
suggest that different chemotherapy regimens may have differential effects on brain volume and cognition.
Future, larger studies focusing on older adults with cancer on different treatment regimens are needed to
confirm these findings.
Trial registration: ClinicalTrials.gov, NCT01992432. Registered on 25 November 2013. Retrospectively
registered.
Keywords: Brain MRI, Brain volume, Chemotherapy, Cancer-related cognitive impairment, Breast cancer
Background
Cognitive decline is among the most feared symptoms in
older adults undergoing treatment for cancer [1, 2]. As
cancer incidence increases with age [3] and cognitive
changes frequently occur following cancer systemic
therapy, it is imperative to understand who is most at
risk and what is the neuroanatomical basis underlying
these changes. The majority of patients with breast can-
cer self-report cognitive problems during and after
chemotherapy [4]; however, neuropsychological testing
has yielded widely varying results. Different studies have
reported that 13–70% of patients receiving chemother-
apy demonstrate objective changes, with memory, pro-
cessing speed, and executive function being the most
commonly affected domains [5]. The discrepancy
between patient-reported symptoms and objective
results from neuropsychological testing, the wide range
of results within neuropsychological testing, and the
recent emphasis on individualized care all highlight the
critical need to identify individuals who are especially at
risk for post-therapeutic cognitive decline [6, 7]. The
disparity between subjective, patient-reported cognitive
problems and objective identification of cognitive prob-
lems highlights the need to better understand the neural
correlates of cognitive decline.
Brain magnetic resonance imaging (MRI) can be used
to identify risk factors and imaging-based biomarkers for
adverse cognitive outcomes of chemotherapy treatment
in patients with cancer. Adjuvant chemotherapy for
breast cancer is associated with changes in structural
MRI including an overall decrease of gray matter dens-
ity. However, these studies have been primarily per-
formed in younger cohorts of patients with a mean age
(SD) ranging from 46.3 (6.1) to 52.9 (8.6) years [8–10].
Older adults may be at increased risk for cognitive de-
cline. For example, a longitudinal study of individuals
aged 46–86 years demonstrated that aging is associated
with a reduction in brain volume, estimated at 0.5–1.5%
per year in all brain structures [11] and the loss in brain
volume was associated with cognitive decline [12]. How-
ever, there is a gap in knowledge regarding whether
chemotherapy is associated with accelerated loss of brain
volume in older adults with breast cancer.
This is a pilot longitudinal study to evaluate the asso-
ciation between changes in brain volume and cognition
in older women with breast cancer after receiving adju-
vant chemotherapy. The overall goal of the study was to
evaluate the longitudinal volume measurements of brain
structures that were highly associated with cogni-
tion—total gray matter, frontal lobe, and temporal
lobe—among older adults with breast cancer [13]. We
hypothesized that the volumes of the total gray mat-
ter, the frontal lobe, and the temporal lobe would be
reduced in older women with breast cancer from pre
to post-adjuvant chemotherapy and that these changes
would be accompanied by decreased performance in
neuropsychological testing. Recent literature shows
that different chemotherapy regimens may exert
different neurotoxicity profiles [14]. Thus, we per-
formed an exploratory hypothesis-generating analysis
to examine how different chemotherapy regimens af-
fected brain volumes in our study cohort.
Methods
The present study is a frequency matched case-control
study. Cases were women aged ≥ 60 years with stage
I–III breast cancer. The inclusion criteria for cases
were: (1) stage I–III breast cancer in patients sched-
uled to receive adjuvant chemotherapy; (2) able to
provide informed consent; (3) age 60 years and older;
(4) of any performance status; and (5) no history of
neurological or psychiatric disorders or stroke. The
exclusion criteria for cases were: (1) metastatic dis-
ease or (2) MRI exclusion criteria such as claustro-
phobia, cardiac pacemaker, and orbital metal
implants. Age-matched and sex-matched healthy con-
trols with no history of cancer or chemotherapy ex-
posure were recruited from the community with the
same inclusion and exclusion criteria except the
healthy controls did not have a cancer diagnosis. This
research protocol was approved by the Institutional
Chen et al. Breast Cancer Research  (2018) 20:38 Page 2 of 11
Review Board at City of Hope National Medical Cen-
ter. Written informed consent was obtained from all
study participants.
The pre-chemotherapy assessment, including a brain
MRI scan and neuropsychological testing with the US
National Institutes for Health (NIH) Toolbox for Cognition,
was performed after surgery but before the start of adjuvant
therapy (time point 1, baseline). The follow-up assessment
for chemotherapy-treated patients was conducted around
one month after the last infusion of chemotherapy (time
point 2). The healthy control group underwent the same
assessments at matched intervals.
Brain MRI scans and brain volume measurements
Imaging parameters
All brain MRI scans were performed on the same 3T
VERIO Siemens scanner (Siemens, Erlangen, Germany).
Sagittal T1-weighted three-dimensional (3D) magnetization
prepared rapid gradient echo (MPRAGE) imaging data
were acquired with the following parameters: echo time
(TE) = 2.94 ms, repetition time (TR) = 1900 ms, fractional
anisotrophy (FA) = 9°, bandwidth = 170 Hz/pixel, imaging
matrix = 256 × 176 pixels, with a voxel size of 1 × 1 ×
1 mm3 in the axial, coronal, and sagittal planes.
Brain volume measurement
Brain volumes were measured using the cloud-based
Neuroreader™ software (Horsens, Denmark, https://
brainreader.net/) [15–18]. This software is a commer-
cially available and it can be used for automated volu-
metric measurement of segmented brain structures from
3D T1-weighted MPRAGE data. The brain volume seg-
mentation of the imaging data was repeated three times
to ensure accuracy of the automated segmentations. The
output of this data analysis was carefully examined by
the team for consistency. No significant inconsistency
was noted during data analysis. The segmented brain
structures included total gray matter, total white matter,
frontal lobe, temporal lobe, parietal lobe, and occipital
lobe. The volumes of bilateral lobes were combined as
an overall lobe in statistical analysis.
Neuropsychological testing
All study participants completed neuropsychological
testing using the NIH Toolbox for Cognition [19]. The
NIH Toolbox (http://www.healthmeasures.net/explore-
measurement-systems/nih-toolbox) uses a computerized
format with national standardization. The cognition bat-
tery consists of seven measures that target the subdo-
mains of executive function, episodic memory, language,
processing speed, working memory, and attention. This
battery generates three composite scores and seven indi-
vidual scores.
Demographic and disease characteristics
The participants’ demographic characteristics, including
age, education, race, and ethnicity, were obtained
through a self-reported questionnaire. Disease stage and
treatment information (the chemotherapy regimen) were
obtained through medical record abstraction. The
chemotherapy toxicity risk scores (as defined by the
Cancer and Aging Research Group) were calculated util-
izing results from the medical records and the geriatric
assessment questionnaire [20, 21]. Details of the ques-
tionnaire included in this assessment have been previ-
ously published [22]. Treatment duration was calculated
as days between the first infusion and last infusion of
chemotherapy.
Statistical analysis
All participants were female. The healthy controls were
frequency matched to the patients with breast cancer in
terms of age distribution. Unconditional logistic regres-
sion was used to compare the patients with breast
cancer and healthy controls in terms of ethnicity and
education. All healthy controls were white, thus the
Fisher’s exact test was used to compare the race/ethni-
city distribution between the patients and the healthy
controls.
Statistical analysis was performed on the volume mea-
surements from brain segmentation output using the
Neuroreader™ image processing pipeline. For chemother-
apy patients and healthy controls, the mean and stand-
ard deviations were presented for total white matter,
total gray matter, and lobar volumes. All brain volumes
were controlled using measured total intracranial
volume (mTIV) and expressed as mTIV ratios. Changes
were calculated as mTIV ratios at time point 2 minus
mTIV ratios at time point 1. Percent changes were
calculated as changes divided by mTIV ratios at time
point 1. Linear mixed modeling, taking into consider-
ation the correlation of repeated measurements within
subjects, was used for longitudinal brain volume analysis
[23]. Within-subject correlation was accounted for using
a compound symmetry covariance structure. Time
points (1 and 2) and group (patients receiving chemo-
therapy versus healthy controls) were both considered
categorical fixed effects in the model. The interaction
term of the group indicator with time point was in-
cluded in the model to examine whether the changes in
brain volume in the chemotherapy patient group differed
significantly from those of the healthy control group.
Using this linear mixed effect model with a compound
symmetry covariance structure to account for correl-
ation between repeated measurements, we examined: (1)
whether there were any differences in segmented brain
volumes between the chemotherapy group and the
healthy control group at time point 1 and time point 2;
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(2) whether there were any significant changes from
time point 1 to time point 2 within the chemotherapy
group and the healthy control group; and (3) whether
the brain volume changes differed by group (p for inter-
action). All statistical tests were two-sided. Since the
main hypothesis for this study focused on total gray
matter, frontal lobe, and temporal lobe, a conservative
Bonferroni method was used to correct for multiple test-
ing, with p values <0.01 considered statistically signifi-
cant. The Bonferroni method was not applied to the
statistical tests involving the neuropsychological data or
any other analyses. Data were analyzed using SAS 9.3
(SAS Institute, Cary, NC, USA).
Results
The demographic data for all study participants are sum-
marized in Table 1. The participants consisted of 16
consecutive eligible patients with breast cancer (mean
age 67, SD 5.39 years) and 14 age-matched and sex-
matched healthy controls (mean age 67.8, SD 5.24 years).
A total of 15 healthy controls were initially enrolled;
however, one healthy control did not have the sagittal
T1-weighted 3D MPRAGE sequence included in the
brain MRI scan and hence was not included in the final
analysis. There were no significant differences between
the chemotherapy group and the healthy control group
in terms of age or overall education (p = 0.51). All study
participants were female and were right-handed. The
chemotherapy group included 11 (68.8%) white women
and 5 (31.2%) black women, while all healthy controls
(n = 14) were white women (p = 0.04). There was no
difference in ethnicity between groups. There were 5
(31.3%) patients with stage I, 8 (50.0%) patients with
stage II, and 3 (18.7%) patients with stage III breast
Table 1 Demographic data of the study participants
Chemotherapy group (n = 16) Healthy controls (n = 14)
Variable Number Percent Number Percent
Age, years
Mean (SD) 67.0 (5.39) N/A 67.8 (5.24) N/A
Range 60–82 N/A 60–78 N/A
Race
White 11 68.8% 14 100%
Black 5 31.2% 0 0.0%
Ethnicity
Hispanic or Latina 2 12.5% 2 14.3%
Non-Hispanic 14 87.5% 12 85.7%
Education
High school 4 25.0% 1 7.1%
Some college or junior college 6 + 2 50.0% 4 + 4 57.1%
College degree 3 18.8% 3 21.4%
Post college 1 6.2% 2 14.4%
Stage
I 5 31.3% N/A N/A
II 8 50.0% N/A N/A
III 3 18.7% N/A N/A
Regimen
TC 7 43.75% N/A N/A
TCPH 1 6.25% N/A N/A
Paclitaxel/trastuzumab 4 25.0% N/A N/A
Docetaxel/cyclophosphamide/PH 1 6.25% N/A N/A
Carboplatin/paclitaxel 1 6.25% N/A N/A
ddAC – paclitaxel 1 6.25% N/A N/A
TAC 1 6.25% N/A N/A
Abbreviations: TC docetaxel and cyclophosphamide, TCPH docetaxel, carboplatin, pertuzumab, trastuzumab, Docetaxel/cyclophosphamide/PH docetaxel,
cyclophosphamide, pertuzumab, trastuzumab, ddAC - Paclitaxel dose-dense doxorubicin and cyclophosphamide followed by paclitaxel, TAC docetaxel, doxorubicin,
and cyclophosphamide, N/A not applicable
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cancer. Out of the 16 patients, 7 (43.8%) received doce-
taxel and cyclophosphamide (TC regimen) and 9 (56.2%)
received a chemotherapy regimen other than TC: 4 (25.
0%) received paclitaxel and trastuzumab, and the
remaining 5 patients (each 6.25%) received different
chemotherapy regimens as noted in Table 1. The median
duration of the chemotherapy treatment was 63 days
(range 42–112 days). The median time between treat-
ment completion and the time point 2 MRI was 22 days
(range 1–42 days). The median time interval between
treatment completion and neurocogitive testing was
22 days (range 1–98 days).
Table 2 presents the summary of the brain volume
measurements normalized by mTIV of total gray matter,
total white matter, and lobar structures at time point 1
and time point 2 for both the chemotherapy group and
healthy control group. The volumes of bilateral lobes
were combined as an overall lobe in statistical analysis.
Representative images from brain segmentation output
are shown in Fig. 1. There were no significant differ-
ences between the chemotherapy group and the healthy
control group (p > 0.05) in total gray matter, total white
matter, the segmented lobar brain structures at time
point 1 (baseline) or at time point 2.
Table 3 presents the longitudinal brain volume
changes within each of the two groups from time point
1 to time point 2 and compares the changes between the
two groups (group by time interaction). In the chemo-
therapy group, there were non-significant volume
reductions over time in total gray matter (change = − 2.05,
p = 0.02), significant volume reductions in the frontal lobe
(change = − 0.33, p = 0.003), and non-significant volume
increase in total white matter (change = 1.65, p = 0.06)
from time point 1 to time point 2. However, non-
significant volume reductions over time in total gray
matter (change = − 0.99, p = 0.27) and in the frontal lobe
(change = − 0.27, p = 0.02), and non-significant volume
increase in total white matter (change = 0.90, p = 0.32)
were also observed in the healthy control group, thus the
volume changes between the two groups were not
significantly different. A non-significant reduction was ob-
served in the temporal lobe in the chemotherapy group
(change = − 0.09, p = 0.16) and no significant reduction
was observed for the healthy control group (change = 0.08,
p = 0.25). There was a weak group-by-time interaction in
the temporal lobe (p for interaction = 0.08). There were no
significant reductions in the parietal lobe, the occipital
lobe, or in total white matter in either the chemotherapy
group or the healthy control group.
Further exploratory analyses of the chemotherapy
group revealed that the temporal lobe reduction oc-
curred mainly among patients who received the TC regi-
men (docetaxel and cyclophosphamide) (change = − 0.26,
p = 0.006) (Table 4). Compared to the healthy control
group, the TC group had significant volume reduction in
the temporal lobe (p for interaction = 0.004) (Fig. 2). The
TC group had a reduction in temporal lobe volume of 2.
4% from time point 1 to time point 2, while the non-TC
group and healthy control group did not have a reduc-
tion. Sensitivity analysis by excluding one or two patients
at a time in the TC group did not change the findings.
The TC group also demonstrated significant total gray
matter reduction over time (change = − 3.99, p = 0.002),
although the reduction was not statistically significantly
different from that in the non-TC group (change = − 0.56,
p for interaction = 0.04) or the healthy control group
(change = − 0.99, p for interaction = 0.05). There were no
differences between the TC group and non-TC group in
age, education, race/ethnicity, or cancer stages. There
were also no significant differences between the TC group
and non-TC group in the chemotherapy toxicity risk score
and measures of physical function including activities of
daily living measured by the Medical Outcome Study
(MOS) Physical Health scale and the Instrumental Activ-
ities of Daily Living (IADL) scale. Furthermore, there were
no significant differences in brain volume at baseline
Table 2 Measured total intracranial volume (mTIV) and brain volume measurements normalized by mTIV (mTIV ratio)
Chemotherapy group (n = 16) Healthy control group (n = 14)
Time point 1 Time point 2 Time point 1 Time point 2
Mean SD Mean SD Mean SD Mean SD
mTIV (ml) 1718.46 114.77 1707.12 110.23 1734.76 130.92 1714.87 119.83
Volume (mTIV ratio)
Total white matter 26.75 3.15 28.40 4.77 27.94 3.33 28.84 2.57
Total gray matter 31.70 3.39 29.64 4.21 31.24 3.81 30.26 4.62
Frontal lobe 20.23 1.86 19.89 1.66 20.17 1.52 19.90 1.70
Parietal lobe 10.70 0.79 10.63 0.81 10.78 0.81 10.70 0.90
Occipital lobe 5.29 0.51 5.30 0.59 5.48 0.48 5.46 0.53
Temporal lobe 11.05 0.71 10.96 0.72 11.30 0.82 11.38 0.82
SD standard deviation
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between the two groups. However, the patients in the TC
group had a shorter chemotherapy duration (an average of
60 days), than the non-TC group (average of 86 days,
p = 0.003).
Table 5 summarizes all neuropsychological testing
scores with the NIH Toolbox for Cognition in both the
chemotherapy group and the healthy control group at
time point 1 and time point 2. There were no significant
differences in the neuropsychological scores between the
chemotherapy group and the healthy control group at
time point 1. For most of the domains, there were no
significant changes over time in either the chemotherapy
group or the healthy control group. The healthy control
group demonstrated higher scores at time point 2 com-
pared to time point 1, possibly due to practice effect
(Table 5). However, for the chemotherapy group as a
whole, most of the time point 2 scores did not increase
as expected from practice effect. On the contrary, the
chemotherapy group had a decrease in the oral reading
recognition scores (change = − 3.71) compared to healthy
controls (change = 0.09, p for interaction = 0.11). Further
subgroup analysis showed that the reduction in oral
reading recognition scores was only observed in the pa-
tients who received the TC regimen (change = − 6.94)
compared to the healthy control group (change = 0.09,
p for interaction = 0.02) (Table 6 and Fig. 2). There
was no significant correlation between the volume re-
duction in the temporal lobe or total gray matter and
decreases in the oral reading recognition score.
Among patients who received chemotherapy, the
Spearman’s correlation coefficient was 0.27 (p = 0.31);
among the patients who received the TC regimen, the
Spearman’s correlation coefficient was 0.17 (p = 0.70).
Discussion
To the best of our knowledge, the current study is one
of few prospective longitudinal studies examining
changes in brain volume on brain MRI and neurocogni-
tive function among older adults with breast cancer
receiving chemotherapy. There were no significant dif-
ferences in the segmented brain volumes between the
healthy control group and the chemotherapy group;
however, exploratory analyses demonstrated temporal
lobe volume reduction in the chemotherapy subgroup of
patients who received the TC regimen. Patients who
received the TC regimen also had a decreased score on
the oral reading recognition test.
Several of our findings are in general accord with prior
structural neuroimaging studies of chemotherapy and
cognition in patients with breast cancer. Most reported
neuroimaging studies of cancer-related cognitive impair-
ment were cross-sectional in design and were conducted
in breast cancer survivors. These prior studies reported
reduced gray matter volume [24], smaller total brain
volume and gray matter volume [25], and decreased gray
matter density [26]. In a cross-sectional study of breast
cancer survivors treated with chemotherapy, Inagaki and
colleagues showed significant differences in regional
Fig. 1 Representative images of segmented brain volumes in a study participant. This set of images shows segmented brain structures in sagittal,
axial, and coronal planes (a, b, c)
Table 3 Longitudinal volume changes (in measured total intracranial volume (mTIV) ratio) within the chemotherapy group and the
healthy control group
Chemotherapy group (n = 16) Healthy control group (n = 14) p comparing groups*
changes in mTIV ratio (SD) p value changes in mTIV ratio (SD) p value
Total white matter 1.65 (3.63) 0.06 0.90 (2.91) 0.32 0.54
Total gray matter −2.05 (3.38) 0.02 −0.99 (3.18) 0.27 0.38
Frontal lobe −0.33 (0.39) 0.003 −0.27 (0.44) 0.02 0.68
Temporal lobe −0.09 (0.31) 0.16 0.08 (0.16) 0.25 0.08
Parietal lobe −0.07 (0.27) 0.27 −0.08 (0.22) 0.23 0.89
Occipital lobe 0.01 (0.18) 0.77 −0.02 (0.14) 0.65 0.60
*p values from comparison of volume changes between the two groups (group-by-time interaction)
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brain volume between the chemotherapy and non-
chemotherapy groups after 1 year using a different im-
aging analysis method [27]. However, these differences
in regional brain volume were not noted in a 3-year
interval in the same study. A long-term survivorship
study confirmed the late effects (more than 9 years) of
adjuvant chemotherapy with gray matter reduction in
the posterior parts of the brain in breast cancer survi-
vors exposed to chemotherapy [24].
There are few other longitudinally designed studies of
brain structural alterations in patients with breast cancer
receiving adjuvant chemotherapy [9, 10, 28, 29]. McDonald
and colleagues conducted a longitudinally designed study
with a similar number of chemotherapy patients and
healthy controls (17 patients with breast cancer on chemo-
therapy, 12 patients with breast cancer no chemotherapy,
and 18 healthy controls), but in a younger age group at
baseline: 50.6 (6.5) to 52.7 (7.2) mean years of age (SD).
Their study showed acute reduction in gray matter density
one month after completion of chemotherapy with a
similar timeframe as our study. Their study also showed a
partial recovery at 1-year follow-up assessment [9].
Additional longitudinal brain structural MRI studies pre-
sented further evidence of a similar pattern of gray matter
alterations [10, 28]. Both cross-sectional and
longitudinal studies have clearly identified a decrease
in gray matter in the chemotherapy group compared
to the non-chemotherapy cancer control group or
healthy controls [13]. However, the gray matter reduc-
tion in the chemotherapy group observed in our
study was not more than the reduction in the healthy
control group. This lack of a significant difference
could be due to our modest sample size and not hav-
ing enough power to detect a modest change.
Our study showed frontal lobe volume reduction in
the healthy control group as well as in the chemotherapy
group. This result was not entirely surprising since our
study cohort was older, ranging from 60 to 82 years of
age, and older adults may experience some brain volume
loss over time. Our study results were generally in line
with volumetric studies of healthy aging, in which grad-
ual gray matter atrophy has been shown as part of the
normal aging process in several brain areas, especially in
the frontal and temporal lobes [30, 31]. We identified
frontal lobe volume loss in the healthy control group
over a short interval of 2–5 months, which we had not
anticipated; however, in review of the literature, a prior
study showed extensive cortical reduction in the pre-
frontal cortex and temporal lobe after just 1 year in
healthy elderly participants at 60–91 years of age,
Table 4 Comparison of longitudinal volume changes in the chemotherapy subgroups and the healthy control (HC) group
Non-TC (n = 9) TC (n = 7) HC (n = 14) TC vs. non-TC, p Non-TC vs. HC, p TC vs. HC, p
Total white matter 0.04 3.25 0.90 0.46 0.67 0.24
Total gray matter −0.56 −3.99* − 0.99 0.04 0.75 0.05
Frontal lobe −0.34 −0.32 − 0.27 0.91 0.68 0.80
Temporal lobe 0.04 −0.26* 0.08 0.02 0.70 0.004
Parietal lobe −0.13 0.01 −0.08 0.26 0.64 0.42
Occipital lobe 0.04 −0.03 −0.02 0.40 0.38 0.92
The TC subgroup (n = 7) included the patients on the docetaxel and cyclophosphamide chemotherapy regimen. The non-TC subgroup (n = 9) included the patients
on a chemotherapy regimen other than the TC regimen. *p < 0.01
Fig. 2 Longitudinal changes in temporal lobe volume (a) and Oral Reading Recognition Score (b). This figure shows the changes in temporal
lobe volumes and scores for both the chemotherapy group including docetaxel and cyclophosphamide (TC yes) and non-TC (TC no) subgroups
and the healthy control group. TC (TC yes) indicates the chemotherapy regimen consisting of docetaxel and cyclophosphamide. Non-TC (TC no)
indicates a chemotherapy regimen other than the TC regimen. mTIV, measured total intracranial volume
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indicating accelerated brain atrophy with increasing age
[32]. A study combining analyses of 56 longitudinal
studies on the aging brain showed rapid brain volume
loss after 60 years of age [33]. Furthermore, prior
research has pointed out that some conditions, such as
hypertension, subclinical depression, and preclinical
neurodegenerative disease, may accelerate brain volume
loss [34, 35]. These potentially confounding variables
were not controlled for in the healthy control group in
our study. Celle et al. reported significant blood
pressure-related decreases in gray matter volume in the
left superior and middle frontal gyrus [34]. There were
also reports of depressive symptoms at a subclinical level
in late life being associated with decreased volumes in
the frontal and temporal lobes [35]. We did not have
detailed blood pressure measurements or information to
evaluate for any subclinical depression or preclinical
neurodegenerative disease in the healthy controls in
our study.
Although when examined as a whole, our study did
not show a significant difference in volume changes in
the temporal lobe between the chemotherapy group and
the healthy control group, we did observe a significant
volume reduction in the temporal lobe in patients who
received the docetaxel and cyclophosphamide (TC) regi-
men compared to the healthy control group. Accom-
panying this reduction in temporal lobe volume, patients
in the TC group also had reductions in oral reading
recognition scores in neuropsychological testing. Other
than length of the chemotherapy treatment, there were
no differences between the TC and non-TC groups in
terms of disease stage, age, physical functions and
chemotherapy toxicity risk score. Furthermore, at base-
line, there was no significant difference in temporal lobe
Table 5 Summary of neuropsychological testing data with NIH Toolbox for Cognition (score and SD)














Crystallized composite 110.87 (16.12) 107.38 (15.57) 110.56 (11.82) 107.05 (18.53) − 0.31 (7.21) − 0.33 (6.44) 1.00
Fluid composite 99.69 (14.43) 99.22 (10.65) 100.23 (14.62) 105.08 (15.85) 0.54 (11.66) 5.86 (11.84) 0.23
Total composite 105.10 (19.11) 101.48 (15.02) 104.14 (15.05) 105.11 (20.37) − 0.95 (10.00) 3.63 (8.78) 0.20
Dimensional change card sort 100.66 (11.83) 101.78 (12.62) 101.70 (7.06) 106.91 (9.64) 1.04 (8.37) 5.13 (12.26) 0.29
Flanker Inhibitory control 95.78 (10.97) 96.92 (9.12) 92.50 (9.25) 99.74 (6.11) − 3.27 (12.33) 2.81 (6.77) 0.11
Working memory 101.45 (16.31) 100.18 (16.35) 107.01 (10.64) 105.00 (17.00) 5.57 (10.19) 4.83 (14.10) 0.87
Oral reading recognition 111.52 (11.95) 103.37 (12.51) 107.80 (12.33) 103.45 (14.00) −3.71 (5.74)* 0.09 (6.91) 0.11
Processing speed 91.29 (14.08) 96.84 (14.06) 91.14 (17.05) 95.39 (16.45) − 0.14 (14.94) − 1.44 (14.94) 0.81
Episodic memory 111.73 (20.06) 103.49 (15.26) 109.70 (21.33) 110.29 (25.05) −2.02 (12.24) 6.80 (21.18) 0.17
Picture vocabulary 107.06 (14.94) 109.13 (16.63) 110.30 (8.88) 107.66 (16.52) 3.23 (9.94) − 1.47 (6.30) 0.14
*p = 0.02
**p comparing change over time between chemotherapy group and healthy control group. Bold numbers indicate key findings
Table 6 Comparison of longitudinal changes in neuropsychological scores in the chemotherapy subgroup and the healthy control
(HC) group
Non-TC (n = 9) TC (n = 7) HC (n = 14) Non-TC vs. HC, p Non-TC vs. TC, p TC vs. HC, p
Crystallized composite −0.17 −0.49 − 0.33 0.96 0.92 0.96
Fluid composite −4.23 6.67 5.86 0.04 0.06 0.88
Total composite − 2.94 1.58 3.63 0.12 0.35 0.64
Dimensional change card sort −1.99 4.94 5.13 0.11 0.19 0.97
Flanker inhibitory control −5.29 −0.69 2.82 0.07 0.38 0.46
Working memory 5.31 5.90 4.83 0.93 0.93 0.85
Oral reading recognition −1.22 −6.94 0.09 0.62 0.07 0.02
Processing speed −6.17 7.59 −1.45 0.45 0.07 0.18
Episodic memory −4.85 1.62 6.80 0.12 0.46 0.52
Picture vocabulary −0.05 7.46 −1.48 0.68 0.08 0.02
Picture vocabulary −0.05 7.46 −1.48 0.68 0.08 0.02
The TC subgroup (n = 7) included the patients on the docetaxel and cyclophosphamide chemotherapy regimen. The non-TC subgroup (n = 9) included the patients
on a chemotherapy regimen other than the TC regimen. Bold numbers indicate key findings
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volume between the two groups. Our study results point
to a potential treatment-specific loss of temporal lobe
volume and decrease in neuropsychological testing score
specifically in patients treated with the TC regimen.
The temporal lobe has been shown to be one of the
brain structures affected in patients with breast cancer
treated with chemotherapy [27]. Brain structures in the
medial temporal lobe, such as the parahippocampal
gyrus, have been shown to have reduction in volume in
patients treated with chemotherapy [27]. The oral read-
ing recognition test in the NIH Toolbox for Cognition
assesses reading decoding and it measures the partici-
pant’s ability to pronounce single words or letters on the
computer screen [36]. The TC regimen consisted of
docetaxel and cyclophosphamide and it is usually given
every 21 days for four cycles. Since a taxane was also
included in all of the non-TC regimens, docetaxel was
less likely to be implicated. On the other hand, cyclo-
phosphamide (which was only included in some of the
non-TC regimens) is known to cross the blood-brain
barrier resulting in direct neurotoxicity [37], which
might have played a role in the reduction of oral reading
recognition scores in the TC group. However, our
explanation is mostly based on speculation and the
definitive mechanisms responsible for reduction in
temporal lobe volume and oral reading recognition
scores in the subgroup of patients treated with the TC
regimen cannot be extrapolated from this pilot study.
Furthermore, we acknowledge that the oral reading rec-
ognition test is viewed as a “hold” test to estimate base-
line intelligence and therefore it is possible our finding
of reduced scores on this measure reflects the effects of
regression to the mean rather than chemotherapy-
related impact. Nevertheless, this novel finding has
provided a direction for our future studies with larger
cohorts to understand how different chemotherapy regi-
mens affect brain volume and cognition in older women
with breast cancer.
There were differences between our study and the pub-
lished literature. For example, we did not observe a greater
brain volume reduction in total gray matter and the frontal
lobe in the chemotherapy group as compared to the healthy
control group [13]. There are several possible reasons for
the discrepancy between our data and the prior studies, in-
cluding differences in study methodology (i.e. participant
demographics and imaging analysis methodology), and the
older age of our study participants (ranging from 60 to
82 years) than those in the reported studies. The effect of
chemotherapy on brain volumes is largely unknown
within a short interval (2–5 months) in this older
population. Additionally, we used Neuroreader™ soft-
ware for brain segmentation while the previous stud-
ies used other methods such as voxel-wise analysis
[38]. In addition, Neuroreader™ reports the actual
volumes of brain structures based on anatomical
boundaries of specific brain structures. Therefore, it is
possible that there might be significant alterations in
the voxel-wise probability, which are not detected in
segmented brain volumes. The heterogeneity of
chemotherapy regimens for the chemotherapy group
may also play a role in the varying brain volume
changes, as neurotoxicity related to chemotherapy
treatment may differ depending on the therapy given.
There are several limitations to this study. First of all,
a modest number of participants were evaluated in this
pilot study pre and post chemotherapy over a short time
course of 2–5 months. Second, the majority of our par-
ticipants were non-Hispanic white women, thus limiting
the generalizability of our findings to other races. Third,
some comorbidities such as high blood pressure and
subclinical depression, which may be associated with
brain volume loss in the healthy population, were not
collected in this study. In addition, our study lacked a
non-chemotherapy breast cancer control group, which
may have helped to assess the effect of breast cancer as
a source of brain structural changes. Furthermore, differ-
ent methods such as voxel-based morphometry (VBM)
may be utilized to assess the changes in brain volume
associated with chemotherapy. It is conceivable that
there might be alterations in the voxel-wise gray or
white matter probability obtained with the VBM method
that was not detected in our study. Last, although we
did observe a larger reduction in the temporal lobe in
the TC treated patients, we should caution against draw-
ing any definitive conclusions, given the limitations of
working with such a small sample size and the possibility
of exaggerated effect size.
Despite these limitations, there are strengths in this study
utilizing brain MRI to evaluate brain volume changes
among patients receiving chemotherapy. Our study is
unique in its focus on older women with breast cancer re-
ceiving different adjuvant chemotherapy regimens. Older
patients with cancer are potentially vulnerable for cognitive
decline, possibly from accelerated aging. However, few
studies have taken advantage of utilizing the non-invasive
brain MRI to study neuro-correlates of cancer-related cog-
nitive impairment in the older population. In addition, the
availability of the healthy control group in our study en-
abled us to compare volume changes and to identify vol-
ume reduction beyond what is expected in healthy aging.
Conclusions
We observed no significant differences in the segmented
brain volumes between patients receiving chemotherapy
and the healthy control group; however, exploratory ana-
lyses demonstrated a treatment-specific reduction in both
temporal lobe volume and oral reading recognition scores
in the subgroup of older patients who received a regimen
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consisting of docetaxel and cyclophosphamide. Further
studies should be conducted to examine the effect of spe-
cific chemotherapies on brain structure. Additional longi-
tudinal studies with a larger sample size and longer
follow-up intervals are needed to understand the mechan-
ism and to validate the results from this pilot study.
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